Neuroone Medical Technologies R&D Spending Growth & History (NMTC)
Neuroone Medical Technologies's r&d spending was $5.0M for fiscal 2025.
View full Neuroone Medical Technologies company overviewNeuroone Medical Technologies annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | $5.0M | −$81,819 | −1.62% |
| 2024 | 2024-09-30 | $5.1M | −$1.9M | −27.02% |
| 2023 | 2023-09-30 | $6.9M | $2.0M | +40.80% |
| 2022 | 2022-09-30 | $4.9M | $1.0M | +25.59% |
| 2021 | 2021-09-30 | $3.9M | $1.8M | +89.08% |
| 2020 | 2020-09-30 | $2.1M | $546,602 | +35.74% |
| 2019 | 2019-09-30 | $1.5M | $814,103 | +113.85% |
| 2018 | 2018-09-30 | $715,086 | — | — |
| 2017 | 2017-12-31 | $735,333 | — | — |
Neuroone Medical Technologies quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-06-30 | $1.4M | $242,668 | +20.52% |
| Q2 2026 | 2026-03-31 | $1.5M | −$42,573 | −2.82% |
| Q1 2026 | 2025-12-31 | $1.4M | $217,452 | +18.55% |
| Q4 2025 | 2025-09-30 | $1.1M | $4,364 | +0.39% |
| Q3 2025 | 2025-06-30 | $1.2M | −$12,189 | −1.02% |
| Q2 2025 | 2025-03-31 | $1.5M | $237,095 | +18.62% |
| Q1 2025 | 2024-12-31 | $1.2M | −$311,089 | −20.97% |
| Q4 2024 | 2024-09-30 | $1.1M | −$665,742 | −37.41% |
| Q3 2024 | 2024-06-30 | $1.2M | −$696,838 | −36.84% |
| Q2 2024 | 2024-03-31 | $1.3M | −$432,746 | −25.36% |
| Q1 2024 | 2023-12-31 | $1.5M | −$80,179 | −5.13% |
| Q4 2023 | 2023-09-30 | $1.8M | $341,130 | +23.72% |
| Q3 2023 | 2023-06-30 | $1.9M | $666,161 | +54.36% |
| Q2 2023 | 2023-03-31 | $1.7M | $500,934 | +41.56% |
| Q1 2023 | 2022-12-31 | $1.6M | $503,034 | +47.44% |
| Q4 2022 | 2022-09-30 | $1.4M | $429,947 | +42.64% |
| Q3 2022 | 2022-06-30 | $1.2M | $324,217 | +35.98% |
| Q2 2022 | 2022-03-31 | $1.2M | $123,951 | +11.46% |
| Q1 2022 | 2021-12-31 | $1.1M | $126,304 | +13.52% |
| Q4 2021 | 2021-09-30 | $1.0M | $223,571 | +28.49% |
| Q3 2021 | 2021-06-30 | $901,134 | $453,980 | +101.53% |
| Q2 2021 | 2021-03-31 | $1.1M | $739,327 | +216.11% |
| Q1 2021 | 2020-12-31 | $934,158 | $432,339 | +86.15% |
| Q4 2020 | 2020-09-30 | $784,716 | $323,787 | +70.25% |
| Q3 2020 | 2020-06-30 | $447,154 | $24,373 | +5.76% |
| Q2 2020 | 2020-03-31 | $342,102 | −$94,209 | −21.59% |
| Q1 2020 | 2019-12-31 | $501,819 | $292,651 | +139.91% |
| Q4 2019 | 2019-09-30 | $460,929 | $311,342 | +208.13% |
| Q3 2019 | 2019-06-30 | $422,781 | $197,252 | +87.46% |
| Q2 2019 | 2019-03-31 | $436,311 | $331,266 | +315.36% |
| Q1 2019 | 2018-12-31 | $209,168 | −$25,757 | −10.96% |
| Q4 2018 | 2018-09-30 | $149,587 | — | — |
| Q2 2018 | 2018-06-30 | $225,529 | $68,813 | +43.91% |
| Q1 2018 | 2018-03-31 | $105,045 | $33,004 | +45.81% |
| Q4 2017 | 2017-12-31 | $234,925 | — | — |
| Q2 2017 | 2017-06-30 | $156,716 | — | — |
| Q1 2017 | 2017-03-31 | $72,041 | — | — |
Neuroone Medical Technologies r&d spending trends
Over the last five fiscal years, Neuroone Medical Technologies's r&d spending increased from $2.1M to $5.0M, a change of $2.9M. The latest reported quarter, Q3 2026, shows $1.4M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Neuroone Medical Technologies source filings ↗